JAMJOOM PHARMACEUTICALS FACTORY COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 145.8 SAR | +0.14% |
|
0.00% | +26.78% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 8,050 | 10,206 | - | - |
| Enterprise Value (EV) 1 | 7,766 | 9,888 | 9,721 | 9,551 |
| P/E ratio | 27.5 x | 27.9 x | 25.4 x | 21.4 x |
| Yield | 0.87% | 2.15% | 2.4% | 2.91% |
| Capitalization / Revenue | 7.31 x | 7.74 x | 6.94 x | 6.02 x |
| EV / Revenue | 7.05 x | 7.5 x | 6.61 x | 5.64 x |
| EV / EBITDA | 22.6 x | 22.5 x | 21.1 x | 17.6 x |
| EV / FCF | 31 x | 36.6 x | 26.9 x | 21.6 x |
| FCF Yield | 3.23% | 2.73% | 3.71% | 4.64% |
| Price to Book | - | 6.37 x | 5.59 x | 4.97 x |
| Nbr of stocks (in thousands) | 70,000 | 70,000 | - | - |
| Reference price 2 | 115.0 | 145.8 | 145.8 | 145.8 |
| Announcement Date | 3/25/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 1,101 | 1,319 | 1,470 | 1,694 |
| EBITDA 1 | - | 344.3 | 439 | 459.9 | 541.5 |
| EBIT 1 | - | 313.4 | 411 | 440 | 504 |
| Operating Margin | - | 28.47% | 31.16% | 29.92% | 29.75% |
| Earnings before Tax (EBT) 1 | - | 315.8 | 399 | 451 | 515.5 |
| Net income 1 | 171.3 | 292.4 | 366 | 401.6 | 476.7 |
| Net margin | - | 26.56% | 27.75% | 27.31% | 28.14% |
| EPS 2 | 2.450 | 4.180 | 5.230 | 5.740 | 6.817 |
| Free Cash Flow 1 | - | 250.9 | 270 | 361 | 443 |
| FCF margin | - | 22.79% | 20.47% | 24.55% | 26.15% |
| FCF Conversion (EBITDA) | - | 72.85% | 61.5% | 78.5% | 81.8% |
| FCF Conversion (Net income) | - | 85.79% | 73.77% | 89.88% | 92.92% |
| Dividend per Share 2 | - | 1.000 | 3.140 | 3.495 | 4.240 |
| Announcement Date | 5/4/23 | 3/25/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 298.4 | 292.6 | 207.9 | 385.5 | 348 |
| EBITDA | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income 1 | 84.4 | - | - | - | 103 | 97 |
| Net margin | - | - | - | - | 26.71% | 27.87% |
| EPS | 1.210 | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 7/2/23 | 8/15/23 | 11/8/23 | 3/25/24 | 5/9/24 | - |
1SAR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 284 | 318 | 485 | 655 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | 251 | 270 | 361 | 443 |
| ROE (net income / shareholders' equity) | - | 22.3% | 23% | 22.8% | 24% |
| ROA (Net income/ Total Assets) | - | 19.1% | 20% | 20.4% | 20.8% |
| Assets 1 | - | 1,531 | 1,830 | 1,966 | 2,289 |
| Book Value Per Share 2 | - | - | 22.90 | 26.10 | 29.40 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 45.2 | 65 | 45 | 43 |
| Capex / Sales | - | 4.1% | 4.93% | 3.06% | 2.54% |
| Announcement Date | 5/4/23 | 3/25/24 | - | - | - |
1SAR in Million2SAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
145.8
SAR
Average target price
146.6
SAR
Spread / Average Target
+0.56%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +26.78% | 2.72B | |
| +25.24% | 45.32B | |
| +34.85% | 24.51B | |
| +29.56% | 16.85B | |
| +21.32% | 14.62B | |
| +70.51% | 14.16B | |
| -0.05% | 6.79B | |
| +15.74% | 5.82B | |
| -8.87% | 5.73B | |
| +10.29% | 4.93B |
- Stock Market
- Equities
- 4015 Stock
- Financials Jamjoom Pharmaceuticals Factory Company
